Monday, October 06, 2008

Genentech /OSI - Avastin + Tarceva: clinical trials, ain't they a bitch?!

Genentech and OSI Pharmaceuticals have announced top line results from a phase III study evaluating the combination of Avastin and Tarceva as second-line treatment for advanced non-small cell lung cancer.

The trial did not meet its primary endpoint.

No comments: